FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225676834> ?p ?o ?g. }

• W4225676834 endingPage "669" @default.
• W4225676834 startingPage "659" @default.
• W4225676834 abstract "BACKGROUND. CT-based criteria for assessing the gastrointestinal stromal tumor (GIST) response to tyrosine kinase inhibitor (TKI) therapy are limited in part because tumor attenuation is influenced by treatment-related changes including hemorrhage and calcification. The iodine concentration may be less impacted by such changes. OBJECTIVE. The purpose of this study was to determine whether the dual-energy CT (DECT) vital iodine tumor burden (TB) allows improved differentiation between treatment responders and nonresponders among patients with metastatic GIST who are undergoing TKI therapy compared with established CT and PET/CT criteria. METHODS. An anthropomorphic phantom with spherical inserts mimicking GIST lesions of varying iodine concentrations and having nonenhancing central necrotic cores underwent DECT to determine a threshold iodine concentration. Forty patients (25 women and 15 men; median age, 57 years) who were treated with TKI for metastatic GIST were retrospectively evaluated. Patients underwent baseline and follow-up DECT and FDG PET/CT. Response assessment was performed using RECIST 1.1, modified Choi (mChoi) criteria, vascular tumor burden (VTB) criteria, DECT vital iodine TB criteria, and European Organization for Research and Treatment of Cancer (EORTC) PET criteria. DECT vital iodine TB criteria used the same percentage changes as RECIST 1.1 response categories. Progression-free survival was compared between responders and nonresponders for each response criterion by use of Cox proportional hazard ratios and Harrell C-indexes (i.e., concordance indexes). RESULTS. The phantom experiment identified a threshold of 0.5 mg/mL to differentiate vital from nonvital tissue. With use of the DECT vital iodine TB, median progression-free survival was significantly different between responders and nonresponders (623 vs 104 days; p < .001).. For nonresponders versus responders, the hazard ratio for disease progression for DECT vital iodine TB was 6.9 versus 7.6 for EORTC PET criteria, 3.3 for VTB criteria, 2.3 for RECIST 1.1, and 2.1 for mChoi criteria. The C-index was 0.74 for EORTC PET criteria, 0.73 for DECT vital iodine TB criteria, 0.67 for VTB criteria, 0.61 for RECIST 1.1, and 0.58 for mChoi criteria. The C-index was significantly greater for DECT vital iodine TB criteria than for RECIST 1.1 (p = .02) and mChoi criteria (p = .002), but it was not different from that for VTB and EORTC PET criteria (p > .05). CONCLUSION. DECT vital iodine TB criteria showed performance comparable to that of EORTC PET criteria and outperformed RECIST 1.1 and mChoi criteria for response assessment of metastatic GIST treated with TKI therapy. CLINICAL IMPACT. DECT vital iodine TB could help guide early management decisions in patients receiving TKI therapy." @default.
• W4225676834 created "2022-05-05" @default.
• W4225676834 creator A5000184427 @default.
• W4225676834 creator A5010901268 @default.
• W4225676834 creator A5013254368 @default.
• W4225676834 creator A5016142693 @default.
• W4225676834 creator A5018234323 @default.
• W4225676834 creator A5037688873 @default.
• W4225676834 creator A5042346861 @default.
• W4225676834 creator A5046601855 @default.
• W4225676834 creator A5048179253 @default.
• W4225676834 creator A5048667978 @default.
• W4225676834 creator A5057769816 @default.
• W4225676834 creator A5071760803 @default.
• W4225676834 creator A5077414729 @default.
• W4225676834 creator A5085019142 @default.
• W4225676834 creator A5086568941 @default.
• W4225676834 creator A5091256704 @default.
• W4225676834 date "2022-04-01" @default.
• W4225676834 modified "2023-10-16" @default.
• W4225676834 title "Dual-Energy CT Vital Iodine Tumor Burden for Response Assessment in Patients With Metastatic GIST Undergoing TKI Therapy: Comparison With Standard CT and FDG PET/CT Criteria" @default.
• W4225676834 cites W1987631989 @default.
• W4225676834 cites W1991125452 @default.
• W4225676834 cites W1994279468 @default.
• W4225676834 cites W2021685417 @default.
• W4225676834 cites W2036132222 @default.
• W4225676834 cites W2039010280 @default.
• W4225676834 cites W2076482458 @default.
• W4225676834 cites W2079586464 @default.
• W4225676834 cites W2089532470 @default.
• W4225676834 cites W2094053807 @default.
• W4225676834 cites W2096900586 @default.
• W4225676834 cites W2102192131 @default.
• W4225676834 cites W2105125481 @default.
• W4225676834 cites W2107464631 @default.
• W4225676834 cites W2108549165 @default.
• W4225676834 cites W2114678970 @default.
• W4225676834 cites W2123534406 @default.
• W4225676834 cites W2127970337 @default.
• W4225676834 cites W2142457016 @default.
• W4225676834 cites W2143198513 @default.
• W4225676834 cites W2145938281 @default.
• W4225676834 cites W2147282985 @default.
• W4225676834 cites W2152769688 @default.
• W4225676834 cites W2164210934 @default.
• W4225676834 cites W2196324452 @default.
• W4225676834 cites W2342884021 @default.
• W4225676834 cites W2373606074 @default.
• W4225676834 cites W2508581942 @default.
• W4225676834 cites W2609463126 @default.
• W4225676834 cites W2610542645 @default.
• W4225676834 cites W2771006223 @default.
• W4225676834 cites W2786434813 @default.
• W4225676834 cites W2806944012 @default.
• W4225676834 cites W2937666289 @default.
• W4225676834 cites W2955221429 @default.
• W4225676834 cites W3024404792 @default.
• W4225676834 doi "https://doi.org/10.2214/ajr.21.26636" @default.
• W4225676834 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34668385" @default.
• W4225676834 hasPublicationYear "2022" @default.
• W4225676834 type Work @default.
• W4225676834 citedByCount "5" @default.
• W4225676834 countsByYear W42256768342022 @default.
• W4225676834 countsByYear W42256768342023 @default.
• W4225676834 crossrefType "journal-article" @default.
• W4225676834 hasAuthorship W4225676834A5000184427 @default.
• W4225676834 hasAuthorship W4225676834A5010901268 @default.
• W4225676834 hasAuthorship W4225676834A5013254368 @default.
• W4225676834 hasAuthorship W4225676834A5016142693 @default.
• W4225676834 hasAuthorship W4225676834A5018234323 @default.
• W4225676834 hasAuthorship W4225676834A5037688873 @default.
• W4225676834 hasAuthorship W4225676834A5042346861 @default.
• W4225676834 hasAuthorship W4225676834A5046601855 @default.
• W4225676834 hasAuthorship W4225676834A5048179253 @default.
• W4225676834 hasAuthorship W4225676834A5048667978 @default.
• W4225676834 hasAuthorship W4225676834A5057769816 @default.
• W4225676834 hasAuthorship W4225676834A5071760803 @default.
• W4225676834 hasAuthorship W4225676834A5077414729 @default.
• W4225676834 hasAuthorship W4225676834A5085019142 @default.
• W4225676834 hasAuthorship W4225676834A5086568941 @default.
• W4225676834 hasAuthorship W4225676834A5091256704 @default.
• W4225676834 hasConcept C121608353 @default.
• W4225676834 hasConcept C126322002 @default.
• W4225676834 hasConcept C126838900 @default.
• W4225676834 hasConcept C160798450 @default.
• W4225676834 hasConcept C16930146 @default.
• W4225676834 hasConcept C191897082 @default.
• W4225676834 hasConcept C192562407 @default.
• W4225676834 hasConcept C207103383 @default.
• W4225676834 hasConcept C2775922572 @default.
• W4225676834 hasConcept C2779984678 @default.
• W4225676834 hasConcept C2989005 @default.
• W4225676834 hasConcept C31760486 @default.
• W4225676834 hasConcept C44249647 @default.
• W4225676834 hasConcept C535046627 @default.
• W4225676834 hasConcept C539932907 @default.
• W4225676834 hasConcept C71924100 @default.
• W4225676834 hasConceptScore W4225676834C121608353 @default.

• next